The five hallmark genes (METTL6, LCMT1, GSTZ1, ADH4, and ADH1A) are prospective targets for determining the therapeutic efficacy of immunotherapy and targeted therapy, and accurately predict the survival of HCC patients. This evidence concerns the gene ADH1A and hepatocellular carcinoma.